Abliva AB (publ) (ABLI.ST)
SEK 0.42
(-0.83%)
SEK 0.42
(-0.83%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 137 Thousand SEK | 341.94% |
| 2022 | 31 Thousand SEK | -79.47% |
| 2021 | 151 Thousand SEK | -30.09% |
| 2020 | 216 Thousand SEK | 61.19% |
| 2019 | 134 Thousand SEK | 2580.0% |
| 2018 | 5000.00 SEK | -81.48% |
| 2017 | 27 Thousand SEK | 92.86% |
| 2016 | 14 Thousand SEK | -99.44% |
| 2015 | 2.5 Million SEK | -65.02% |
| 2014 | 7.15 Million SEK | 34.06% |
| 2013 | 5.33 Million SEK | 379.34% |
| 2012 | 1.11 Million SEK | -79.97% |
| 2011 | 5.55 Million SEK | 60.91% |
| 2010 | 3.45 Million SEK | -22.11% |
| 2009 | 4.43 Million SEK | 387.83% |
| 2008 | 908.66 Thousand SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - SEK | 0.0% |
| 2024 Q1 | - SEK | -100.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 FY | 137 Thousand SEK | 341.94% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q4 | 137 Thousand SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 FY | 31 Thousand SEK | -79.47% |
| 2022 Q4 | - SEK | -100.0% |
| 2022 Q1 | - SEK | -100.0% |
| 2022 Q3 | 31 Thousand SEK | 0.0% |
| 2021 Q1 | - SEK | -100.0% |
| 2021 Q3 | 85 Thousand SEK | 372.22% |
| 2021 Q4 | 48 Thousand SEK | -43.53% |
| 2021 FY | 151 Thousand SEK | -30.09% |
| 2021 Q2 | 18 Thousand SEK | 0.0% |
| 2020 Q3 | 63 Thousand SEK | -35.05% |
| 2020 FY | 216 Thousand SEK | 61.19% |
| 2020 Q4 | 111 Thousand SEK | 76.19% |
| 2020 Q2 | 97 Thousand SEK | 1112.5% |
| 2020 Q1 | 8000.00 SEK | -83.67% |
| 2019 FY | 134 Thousand SEK | 2580.0% |
| 2019 Q3 | 1.5 Million SEK | 1664.71% |
| 2019 Q1 | - SEK | -100.0% |
| 2019 Q4 | 49 Thousand SEK | -96.73% |
| 2019 Q2 | 85 Thousand SEK | 0.0% |
| 2018 Q3 | - SEK | -100.0% |
| 2018 Q2 | 1.27 Million SEK | 634.48% |
| 2018 Q1 | 174 Thousand SEK | 152.17% |
| 2018 FY | 5000.00 SEK | -81.48% |
| 2018 Q4 | 5000.00 SEK | 0.0% |
| 2017 FY | 27 Thousand SEK | 92.86% |
| 2017 Q4 | 69 Thousand SEK | 7000.0% |
| 2017 Q3 | -1000.00 SEK | 98.41% |
| 2017 Q2 | -63 Thousand SEK | -333.33% |
| 2017 Q1 | 27 Thousand SEK | 92.86% |
| 2016 FY | 14 Thousand SEK | -99.44% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | 14 Thousand SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | -100.0% |
| 2015 FY | 2.5 Million SEK | -65.02% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q2 | 2.5 Million SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 FY | 7.15 Million SEK | 34.06% |
| 2014 Q1 | - SEK | 100.0% |
| 2014 Q4 | 1.12 Million SEK | -84.33% |
| 2014 Q3 | 7.15 Million SEK | 0.0% |
| 2013 Q4 | -95 Thousand SEK | -113.14% |
| 2013 FY | 5.33 Million SEK | 379.34% |
| 2013 Q3 | 723 Thousand SEK | -86.45% |
| 2013 Q2 | 5.33 Million SEK | 657.81% |
| 2013 Q1 | 704 Thousand SEK | 18.72% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | 201 Thousand SEK | 0.0% |
| 2012 Q4 | 593 Thousand SEK | 195.02% |
| 2012 FY | 1.11 Million SEK | -79.97% |
| 2012 Q1 | - SEK | -100.0% |
| 2011 Q2 | 2.7 Million SEK | 0.0% |
| 2011 Q4 | 5.55 Million SEK | 0.0% |
| 2011 FY | 5.55 Million SEK | 60.91% |
| 2011 Q1 | - SEK | -100.0% |
| 2011 Q3 | - SEK | -100.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2010 Q1 | - SEK | -100.0% |
| 2010 Q4 | 3.45 Million SEK | 0.0% |
| 2010 FY | 3.45 Million SEK | -22.11% |
| 2010 Q2 | - SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2009 Q3 | - SEK | 0.0% |
| 2009 Q4 | 4.43 Million SEK | 0.0% |
| 2009 FY | 4.43 Million SEK | 387.83% |
| 2009 Q1 | - SEK | 0.0% |
| 2008 FY | 908.66 Thousand SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 99.764% |
| Ziccum AB (publ) | 3.74 Million SEK | 96.344% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.978% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 99.729% |
| Mendus AB (publ) | 28.48 Million SEK | 99.519% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.913% |
| Intervacc AB (publ) | 8.01 Million SEK | 98.291% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 96.868% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.92% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 99.688% |
| Aptahem AB (publ) | 2.63 Million SEK | 94.792% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | 86.763% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -77.922% |
| Fluicell AB (publ) | 3.33 Million SEK | 95.896% |
| Saniona AB (publ) | 16.84 Million SEK | 99.186% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 99.165% |
| Biovica International AB (publ) | 7.29 Million SEK | 98.121% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | 88.612% |
| AcouSort AB (publ) | 10.55 Million SEK | 98.702% |
| Xintela AB (publ) | 78 Thousand SEK | -75.641% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 99.762% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 93.198% |
| OncoZenge AB (publ) | 3000.00 SEK | -4466.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | 11.613% |
| CombiGene AB (publ) | 5.54 Million SEK | 97.529% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.989% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.992% |
| Corline Biomedical AB | 25.03 Million SEK | 99.453% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 97.587% |
| Isofol Medical AB (publ) | 721 Thousand SEK | 80.999% |
| I-Tech AB | 120.86 Million SEK | 99.887% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.898% |
| Cyxone AB (publ) | 5.14 Million SEK | 97.339% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 98.057% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 98.715% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 98.78% |
| Nanologica AB (publ) | 1.44 Million SEK | 90.506% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -158.491% |
| BioInvent International AB (publ) | 71.46 Million SEK | 99.808% |
| Alzinova AB (publ) | 270 Thousand SEK | 49.259% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 99.611% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 90.636% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 95.145% |
| Simris Alg AB (publ) | 4.35 Million SEK | 96.853% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -5.385% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.943% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -495.652% |